**Appendix Table E76. Results from studies assessing the ability of Multiplate Analyzer to predict platelet reactivity during followup (discrete outcome) in patients with ischemic heart disease**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, year****UID****Country****Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Reactivity Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **Outcome status (e.g., HPR+ or HPR-)** | **No. with outcome status within phenotype group** | **Cut-off** | **Comparative metric (OR, RR, HR)** | **95% CI** | **P (between which groups?)****[statistical test]** | **Adjusted?****[YES/NO/NR]****If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| Siller-Matula,200919135705AustriaNR | Clopidogrel 75 mg MD | Impedence aggregometry | Impedence aggregometry | Aggregation measured with PGE1 and ADP | 24 hrs after PCI | Impedence between 16-88 units | Impedence between 16-88 units | In Fig 1D; difficult to interpret | NR | NR | NR | NR | NR | NR | Fig 1D shows shaded area greater than normal range reported in the text |
|  |  |  |  |  |  | Impedence between 16-88 units | Impedence between <16 units | In Fig 1D; difficult to interpret | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | Impedence between <16 units | Impedence between 16-88 units | In Fig 1D; difficult to interpret | NR | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | Impedence between <16 units | Impedence between <16 units | In Fig 1D; difficult to interpret | NR | NR | NR | NR | NR | NR |  |
| Codner, 201222534051IsraelNR | LD: clopidogrel 600 mg and aspirin 100 mg MD: clopidogrel 75 mg/d and aspirin 100 mg/d | MEA | HTPR | MEA>47 AU | 6 months | HTPR at baseline | HTPR at 6 months | 5 | ≥47 | OR (calculated )= 3.3 | 0.8- 13.1 | P = 0.0894[Chi square] |  |  |  |
|  |  |  |  |  |  | HTPR at baseline | responder at 6 months | 8 |  |  |  |  |  |  |  |
|  |  |  |  |  |  | responder at baseline | HTPR at 6 months | 7 |  |  |  |  |  |  |  |
|  |  |  |  |  |  | responder at baseline | responder at 6 months | 37 |  |  |  |  |  |  |  |